ImmunityBio, Inc. IBRX
Last close
7.81
2026-10-26
Market cap
$8.28B
2026-06-30 share count
52-week range
1.95 - 12.43
Valuation FY2025 figures against the last close
P/S73.1x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.38
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $113.3M | $14.7M | $622.0K | $240.0K | $934.0K | $605.0K | $2.2M | $47.0K | $45.0K | $44.0K |
| Cost of revenue | $753.0K | $0 | $0 | $0 | — | — | — | — | — | — |
| Gross profit | $112.5M | $14.7M | $622.0K | $240.0K | — | — | — | — | — | — |
| R&D | — | $190.1M | $232.4M | $248.1M | $196.0M | $139.5M | $112.0M | $55.7M | $42.0M | $29.2M |
| SG&A | — | $168.8M | $129.6M | $102.7M | $135.3M | $71.3M | $46.5M | $42.7M | $57.1M | $95.4M |
| Total operating expenses | $369.3M | $358.9M | $362.9M | $351.5M | $331.2M | $221.5M | $158.5M | $98.4M | $99.2M | $124.5M |
| Operating income | -$256.0M | -$344.2M | -$362.2M | -$351.3M | -$330.3M | -$220.9M | -$156.3M | -$98.4M | -$99.1M | -$124.5M |
| Interest expense | $60.9M | $114.6M | $128.8M | $63.5M | $14.8M | $9.1M | $5.9M | — | $618.0K | $66.0K |
| Pre-tax income | -$351.6M | -$413.6M | -$583.9M | -$417.3M | -$349.8M | -$226.0M | -$160.3M | -$96.7M | -$96.9M | -$121.4M |
| Income tax | $135.0K | $0 | $40.0K | $34.0K | $9.0K | $1.8M | $105.0K | $503.0K | $493.0K | $572.0K |
| Net income | -$351.5M | -$413.6M | -$583.9M | -$417.3M | -$349.8M | -$221.9M | -$157.8M | -$96.2M | -$96.4M | -$120.8M |
| EPS, basic | -0.38 | -0.59 | -1.15 | -1.04 | -0.89 | -0.59 | -0.43 | — | — | — |
| EPS, diluted | -0.38 | -0.62 | -1.15 | -1.04 | -0.89 | -0.59 | -0.43 | -1.22 | -1.20 | -1.47 |
| Shares, diluted (wtd. avg.) | 919.9M | 700.4M | 508.6M | 399.9M | 389.2M | 377.1M | 366.3M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $88.3M | $143.4M | $265.5M | $104.6M | $181.1M | $34.9M | $75.8M | $16.8M | $23.9M | $8.1M |
| Short-term investments | $154.5M | $6.4M | $1.0M | $2.5M | $136.0M | $61.1M | $36.1M | $57.3M | $104.3M | $190.8M |
| Receivables | $42.6M | $2.4M | $0 | — | — | — | — | — | — | — |
| Inventory | $910.0K | $8.3M | $0 | — | — | — | — | — | — | — |
| Total current assets | $314.9M | $184.6M | $294.1M | $140.6M | $334.3M | $111.7M | $55.8M | $88.8M | $132.5M | $205.1M |
| Property, plant and equipment | $114.3M | $137.1M | $146.1M | $143.7M | $82.9M | $72.5M | $60.5M | $76.9M | $76.7M | $18.9M |
| Goodwill | $910.0K | $910.0K | — | — | — | — | — | — | — | — |
| Other intangibles | $13.0M | $14.5M | $17.1M | $20.0M | $1.4M | $1.5M | $0 | $565.0K | $2.8M | $5.1M |
| Total assets | $501.9M | $382.9M | $504.5M | $362.4M | $468.9M | $221.4M | $143.1M | $181.9M | $250.4M | $317.5M |
| Accounts payable | — | — | — | $21.0M | $11.4M | $11.5M | $1.7M | $2.8M | $5.9M | $4.0M |
| Short-term debt | $1.8M | $1.2M | — | — | — | — | — | — | — | — |
| Total current liabilities | $61.8M | $54.9M | $58.3M | $500.9M | $369.0M | $68.1M | $11.6M | $27.3M | $20.9M | $12.6M |
| Total liabilities | $1.00B | $871.1M | $1.09B | $812.2M | $712.8M | $339.9M | $22.4M | $35.9M | $31.6M | $24.1M |
| Retained earnings | -$3.73B | -$3.38B | -$2.96B | -$2.38B | -$1.96B | -$1.62B | -$662.2M | -$595.0M | -$498.7M | -$387.1M |
| Total equity | -$500.5M | -$489.1M | -$585.9M | -$449.8M | -$243.9M | -$118.5M | $16.3M | $81.9M | $218.8M | $293.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$304.9M | -$391.2M | -$366.8M | -$337.5M | -$274.4M | -$171.7M | -$152.1M | -$63.4M | -$48.8M | -$38.6M |
| Depreciation and amortisation | $15.5M | $17.6M | $18.5M | $18.3M | $14.2M | $12.7M | $14.0M | $9.6M | $5.6M | $3.6M |
| Stock-based compensation | $36.8M | $34.4M | $49.2M | $40.2M | $57.2M | $2.2M | $3.4M | $23.4M | $37.0M | $73.9M |
| Capital expenditure | $3.8M | $6.9M | $30.6M | $78.2M | $33.6M | $1.7M | $4.3M | $13.1M | $34.8M | $6.6M |
| Investing cash flow | -$149.8M | -$12.2M | -$30.5M | $27.3M | -$84.9M | -$19.8M | $18.6M | $57.1M | $99.6M | -$113.7M |
| Financing cash flow | $400.2M | $281.6M | $558.3M | $233.6M | $505.4M | $150.7M | $114.3M | -$771.0K | -$35.0M | -$15.6M |
| Buybacks | — | — | — | — | $0 | $0 | $2.5M | $228.0K | $15.2M | $15.8M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001326110-26-000049.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.0K | $45.0K | $47.0K | $2.2M | $605.0K | $934.0K | $240.0K | $622.0K | $14.7M | $113.3M |
| Gross profit | — | — | — | — | — | — | $240.0K | $622.0K | $14.7M | $112.5M |
| Net income | -$120.8M | -$96.4M | -$96.2M | -$157.8M | -$221.9M | -$349.8M | -$417.3M | -$583.9M | -$413.6M | -$351.5M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Material agreement signed Item 1.01
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2836
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AMGN | AMGEN INC | $240.38B | 31.2x | 10.0% |
| GILD | GILEAD SCIENCES, INC. | $196.77B | 23.4x | 2.4% |
| MRNA | Moderna, Inc. | $79.39B | — | -39.9% |
| RVMD | Revolution Medicines, Inc. | $39.42B | — | — |
| BIIB | BIOGEN INC. | $37.24B | 28.7x | 2.2% |
| EXEL | EXELIXIS, INC. | $16.13B | 23.4x | 7.0% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.83B | 31.2x | 21.4% |
| HALO | HALOZYME THERAPEUTICS, INC. | $14.53B | 50.0x | 37.6% |